Intervention not reported
the rate of complete remission and partly remission(no special data in trial of Zhang 2009) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the rate of complete remission and partly remission(no special data… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects of leukopenia after chemotherapy(no special data in trial of Jia 2003, Zhang 2009) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy(no… (very low certainty).
1 finding from 1 review
Intervention not reported
the rate of complete remission and partly remission(no special data in trial of Fu 2011) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the rate of complete remission and partly remission(no special data… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects in digestive system after chemotherapy(no special data in trial of Fu 2011, Liu 2009a, Zhang 2010) · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects in digestive system after chemotherapy(no… (very low certainty).
1 finding from 1 review
Intervention not reported
the toxic and side effects of leukopenia after chemotherapy · patients with induction of remission in advanced or late gastric cancer
It is very uncertain whether the intervention changes the toxic and side effects of leukopenia after chemotherapy (very low certainty).
1 finding from 1 review
Overall survival (OS) · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower overall Survival (OS) compared with surgery alone (high certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N+ OS · patients with resectable gastric cancer
The intervention probably leads to lower lymph node mets analysis ‐ N+ OS (moderate certainty).
1 finding from 1 review
Disease-free survival · patients with resectable gastric cancer
Post‐surgical chemotherapy leads to lower disease Free Survival compared with surgery alone (high certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ 5‐FU based chemotherapy OS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased OS ‐ 5‐FU based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased OS ‐ Platinum‐based chemotherapy OS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased OS ‐ Platinum‐based chemotherapy OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ 5‐FU based chemotherapy DFS · patients with resectable gastric cancer
The intervention probably leads to lower chemobased DFS ‐ 5‐FU based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Chemobased DFS ‐ Platinum‐based chemotherapy DFS · patients with resectable gastric cancer
The intervention showed no clear difference in chemobased DFS ‐ Platinum‐based chemotherapy DFS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T1/2 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T1/2 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Stage OS analysis ‐ T3/4 OS · patients with resectable gastric cancer
The intervention showed no clear difference in stage OS analysis ‐ T3/4 OS (moderate certainty).
1 finding from 1 review
Intervention not reported
Lymph node mets analysis ‐ N‐ OS · patients with resectable gastric cancer
The intervention showed no clear difference in lymph node mets analysis ‐ N‐ OS (moderate certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (dichotomous) · active EoE pediatric patients
It is very uncertain whether mepolizumab 10 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE pediatric patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found